neous spectrum of T-cell neoplasms with widely varying clinical presentation, biologic behavior and overall outcome. 1, 2 The most common CTCL is mycosis fungoides (MF), which can range from a localized, indolent process to an aggressive lymphoma with widespread cutaneous and extracutaneous involvement and large-cell transformation (MF-LCT). This biologic and clinical heterogeneity is a feature shared with other T-cell lymphomas, including systemic peripheral T-cell lymphomas (PTCLs). Also common to both CTCLs and PTCLs is a limited understanding of genetic mechanisms of pathogenesis and progression, the elucidation of which could facilitate classification, prognostication and individualized therapy. For example, accurate classification of CTCLs often requires careful clinical and pathological follow-up over time, and an enhanced understanding of CTCL genetics might allow earlier, more definitive classification. Furthermore, genetic biomarkers that identify patients at greatest risk of aggressive clinical behavior could allow initiation of earlier or more intensive treatment protocols that might lead to better outcomes. Finally, knowledge of CTCL genetics could improve biologic understanding of this group of diseases and facilitate the development of more specific, targeted therapies.
Although CTCLs and PTCLs are clinically distinct groups of diseases, genetic data have highlighted similarities that suggest biologic interconnectedness. For example, we have shown that chromosomal rearrangements of the DUSP22/IRF4 locus on 6p25.3 are seen in about 30% of both primary cutaneous anaplastic large-cell lymphomas (cALCLs) and systemic ALK-negative ALCLs. 3, 4 More recently, we identified recurrent rearrangements of TP63 on 3q28 in PTCLs that were associated with poor clinical outcomes. 4, 5 TP63 encodes p63, a member of the p53 family of transcription factors. Interestingly, although our study was primarily focused on patients with systemic PTCLs, we also identified two patients with unusually aggressive cALCLs that had TP63 rearrangements. Therefore, we undertook the current multi-institutional study to determine the frequency and clinical significance of TP63 rearrangements in an independent series of CTCLs.
We reviewed CTCL biopsy specimens from 136 previously unreported patients (mean age, 60 years; age range, 14-96 years; male:female, 1.4:1). Classification followed World Health Organization criteria and is summarized in Table 1 . All cases were evaluated for p63 protein expression by immunohistochemistry using the 4A4 clone as previously described, 5 defining positivity as nuclear staining in ⩾ 30% of tumor cells. FISH using dual-fusion and/or breakapart TP63 probes was performed as previously described 5 in all cases that were p63 positive by immunohistochemistry. The validity of using immunohistochemistry to select cases for FISH analysis is supported by our previous data, which showed that TP63 fusion transcripts encoded the 4A4 epitope and that these immunohistochemical criteria identified all T-cell lymphomas with TP63 rearrangements. 4, 5 In the current study, we also performed TP63 FISH in 21 additional p63-negative CTCLs and all lacked TP63 rearrangements.
Immunohistochemistry for p63 was positive in 8 of 136 CTCLs tested (6%), including 5 cALCLs, 1 case of Sézary syndrome, and 2 cases of MF-LCT (Table 1) Figure 1d ). FISH was positive in the majority of cells using both dual-fusion ( Figure 1e ) and breakapart probes (not shown), indicating the presence of TBL1XR1/TP63 fusion corresponding to inv(3)(q26q28). Extra copies of the non-rearranged TBL1XR1 and TP63 genes also were present.
We then examined the relationship of the TP63 rearrangement to the development of LCT. The patient first sought medical attention for her skin disease in September 2001. At that time she reported a 6-month history of pruritic scaly papules and plaques involving multiple anatomic sites. We obtained her original skin biopsy from 2001, which had been interpreted as suggestive of evolving MF. The biopsy showed clusters of atypical small lymphocytes, without prominent large cells (Figures 1f and g ). Interestingly, many of the dermal lymphocytes were positive by p63 immunohistochemistry (Figure 1h ), a finding absent in other cases of MF without LCT examined in the current series (Table 1) . FISH demonstrated cells with both the TP63 rearrangement and extra copies of non-rearranged TBL1XR1 and TP63, identical to the subsequent MF-LCT specimen. These findings indicate that TP63 rearrangement and copy number abnormalities involving 3q occurred before the LCT.
The patient's prior medical history was significant for stage IB, grade 2 endometrial adenocarcinoma in 1999 for which she underwent total abdominal hysterectomy/bilateral salpingooophorectomy with pelvic and para-aortic lymphadenectomy. No metastatic carcinoma was identified in the lymph nodes. Because the origins of early cells leading to MF are poorly understood, we reexamined the lymphadenectomy specimen, which showed preservation of the nodal architecture and patent sinuses containing small lymphocytes (Figures 1j and k) . Immunohistochemical staining performed retrospectively demonstrated CD3-positive T cells in and around the sinuses, some of which had nuclear irregularities and were positive for p63 (Figures  1l and m) . FISH identified the presence of TBL1XR1/TP63 fusion and extra copies of both genes in these areas (Figure 1n ) but showed a normal FISH signal pattern in background reactive cells and in the primary endometrial adenocarcinoma (not shown). These results indicate that T lymphocytes with TP63 rearrangement were present in the patient's lymph nodes about 18 months before the clinical development of cutaneous lesions and 2 years before the diagnosis of MF, and strongly suggest that the rearrangement was acquired somatically. In the two previously reported cALCLs with TP63 rearrangements, no tissue preceding diagnosis was available for testing. In one of the patients, multiple biopsies were tested and all bore the TP63 rearrangement, including the diagnostic specimen. In the other patient, only a single biopsy was available for testing. Thus, based on the limited available data, TP63 rearrangement appears to be a rare, early event in CTCL. A combined summary of findings from this and our previous study are shown in Table 1 .
As part of the p53 family, p63 may have an important role in modulating p53 signaling pathways. p63 has two main classes of isoforms, TAp63 and ΔNp63, which differ in the structure of the N-terminal domain. TAp63 has an N-terminal transactivation domain with tumor suppressor activity, whereas ΔNp63 contains a truncated N-terminal domain that has been proposed to confer oncogenic properties.
6,7 TP63 rearrangements encode fusion proteins homologous to ΔNp63, and although the function of p63 fusion proteins has not been reported, mechanisms implicated in the oncogenic properties of ΔNp63 include sequestration of transactivation domain-containing p53 family proteins, direct transcriptional regulatory activity, and modulation of stem cells. 8, 9 The clinical behavior of MF-LCT is more aggressive compared with that of MF without LCT. For example, one study reported a median survival of 37 months in MF-LCT compared with 163 months in MF. 10 Two previously reported cALCLs with TP63 rearrangement 5 and the MF-LCT reported here demonstrated aggressive clinical behavior. The molecular mechanisms that lead to LCT are not completely understood, although LCT has been associated with tumor aneuploidy and immunophenotypic alterations. [11] [12] [13] In our case, the finding that TP63 rearrangement preceded LCT raises the possibility that screening otherwise conventional MF by p63 immunohistochemistry followed by TP63 FISH in positive cases might identify patients at increased risk of LCT. This would be in keeping with the prognostic utility of TP63 rearrangements in other T-cell lymphomas. Specifically, we recently showed that although systemic ALK-negative ALCL had a 5-year overall survival (OS) rate of 52%, FISH identified a subgroup with TP63 rearrangements and 5-year OS of only 17%. 4 However, given the rarity of TP63 rearrangements in CTCLs, a larger study would be necessary to determine the predictive utility of this approach for cutaneous disease.
Of particular interest was the finding that TP63 rearrangement was present in T cells before the clinical diagnosis of MF, raising the possibility that this rearrangement is an initiating event in T-cell lymphomagenesis. Analogously, BCL2 rearrangements have been identified in cells obtained from healthy patients and higher frequency of these cells has been associated with significantly increased risk of developing follicular lymphoma.
14 Investigation of subsequent events that accompany development of MF and subsequent LCT in TP63-rearranged T cells may contribute substantially to understanding CTCL pathogenesis.
In summary, TP63 rearrangements are rare, early events in CTCL and to date have been reported only in patients with aggressive clinical behavior. Further studies are merited to determine the role of clinical testing for p63 expression and/or TP63 rearrangements in CTCL and to investigate strategies to target these rearrangements therapeutically.
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